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Abstract 
Synucleinopathies including Parkinson’s disease (PD), dementia with Lewy bodies 
(DLB) and multiple system atrophy (MSA) are characterized by the abnormal accumulation 
and propagation of α-synuclein (α-syn) pathology in the central and peripheral nervous 
system as Lewy bodies or glial cytoplasmic inclusions. Several antibodies against α-syn have 
been developed since it was first detected as the major component of Lewy bodies and glial 
cytoplasmic inclusions. Over the years, researchers have generated specific antibodies that 
alleviate the accumulation of intracellular aggregated α-syn and associated pathology in 
cellular and preclinical models of synucleinopathies. So far, antibodies have been the first 
choice as tools for research and diagnosis and currently, a wide variety of antibody fragments 
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have been developed as an alternative to full-length antibodies for increasing its therapeutic 
usefulness. Recently, conformation specific antibody-based approaches have been found to 
be promising as therapeutic strategies, both to block α-syn aggregation and ameliorate the 
resultant cytotoxicity, and as diagnostic tools. In this review we summarize different α-syn 
specific antibodies and provide their usefulness in tackling synucleinopathies. 
 
 
Abbreviations 
 
α-Syn – Alpha-synuclein  
AD – Alzheimer’s disease 
CSF – cerebrospinal fluid 
DLB – dementia with Lewy bodies 
ELISA – enzyme-linked immunosorbent assay 
Fab – Fragment antigen-binding 
Fc – Fragment crystallizable region 
GCI – glial cytoplasmic inclusion 
IgG – immunoglobulin G 
kDa - kilodalton 
MSA – multiple systems atrophy 
NAC – non-amyloid component of plaques 
o-α-syn – oligomeric alpha-synuclein 
pS129-α-syn – alpha-synuclein phosphorylated at serine 129 
PD – Parkinson’s disease 
PDD – Parkinson’s disease dementia 
scFv – single chain fragment variable 
t-α-syn – total alpha-synuclein 
VH – heavy variable domain 
VL – light variable domain 
 
 
Introduction 
The synucleinopathies are a group of neurodegenerative disorders characterized by 
the abnormal accumulation and cellular deposition of the protein alpha-synuclein (α-syn). 
This spectrum of neurodegenerative disorders includes Parkinson’s disease (PD), Parkinson’s 
disease dementia (PDD), dementia with Lewy bodies (DLB) and multiple systems atrophy 
(MSA) (Spillantini & Goedert 2000). Collectively, the synucleinopathies are second only to 
Alzheimer’s disease in prevalence and there is no disease-modifying therapy for these 
disorders. However, better understanding and improved therapeutics for the 
synucleinopathies is a healthcare priority as they are associated with increasing age, meaning 
that their incidence is expected to rise given sustained global population aging.  
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The synucleinopathies can be further sub-divided into Lewy body diseases, including 
PD, PDD and DLB, which are characterized by the accumulation of α-syn into spherical 
lesions within neuronal soma called Lewy bodies and in neuronal processes as Lewy neurites 
(Spillantini et al. 1997). Lewy pathology forms in a stereotyped sequence within the brain, 
with such pathological progression thought to underlie clinical progression. In contrast, the 
typical lesions observed in MSA are α-syn accumulations within oligodendroglia, termed 
Papp-Lantos bodies or glial cytoplasmic inclusions (GCI), and lack the distinct spherical 
structure of Lewy bodies (Spillantini et al. 1998a).  
Parkinson’s disease is the most prevalent synucleinopathy and is clinically 
characterized by cardinal motor features of bradykinesia, rest tremor and postural instability 
that are partially ameliorated by dopaminergic therapy (Gelb et al. 1999). Cognitive decline 
often follows motor dysfunction in PD, and is clinically manifest as dementia in 30% of cases 
(Hanagasi et al. 2017). PDD is clinically characterized by executive and attentional deficits, 
often along with visuo-perceptual abnormalities and hallucinations (Aarsland 2016). In 
contrast to PD, where motor dysfunction precedes cognitive decline, DLB patients initially 
present with cognitive symptoms similar to PDD, including executive and attentional deficits 
and prominent complex visual hallucinations (McKeith et al. 2017). Motor dysfunction is not 
universal amongst DLB patients but occurs in parallel with or at a later stage than the 
cognitive symptoms (McKeith et al. 2017). There is a continued debate as to whether PDD 
and DLB are the result of same pathological process or whether these disease entities rather 
should be seen as different manifestations within the same spectrum (Lippa et al. 2007). It 
has also been suggested that the distinct sequence of clinical features in PDD and DLB may 
result from pathology originating at different predilection sites, with PD beginning in the 
motor regions of the brainstem and midbrain, perhaps subsequent to peripheral α-
synucleinopathy, and DLB originating in the olfactory bulb interconnected to cognitive 
regions of the limbic system and neocortex (Rey et al. 2018).    
    MSA is the third most common synucleinopathy diagnosed in patients at an age of 
around 60 years. MSA is relatively rare compared to PD and DLB though is often mis-
diagnosed as PD, especially during the early stages of the disease. However, MSA typically 
follows a more aggressive course than PD with marked autonomic symptoms and usually a 
poor response to dopaminergic medications (Hughes et al. 1992).  
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α-Synuclein 
α-Syn was originally identified in purified preparations of cholinergic vesicles from 
the electric organ of the electric ray from the genus Torpedo (Maroteaux et al. 1988). Initial 
studies on α-syn in neurodegenerative disorders were focused on AD, where high levels of a 
fragment of α-syn corresponding to amino acids 61-95 now termed the non-amyloid 
component of plaques (NAC), was reported in senile plaques (Ueda et al. 1993). α-Syn was 
first associated with the disorders now termed synucleinopathies when a kindred with 
familial PD originating from the Italian village of Contursi Terme was reported to have a 
point mutation in the α-syn gene SNCA (Polymeropoulos et al. 1997). Following this original 
paper, Spillantini and colleagues then reported the presence of α-syn in Lewy bodies in PD 
and DLB (Spillantini et al. 1997) and later in Papp-Lantos bodies/GCI in MSA (Spillantini et 
al. 1998a). Since then, further genetic studies have confirmed point mutations in SNCA 
(A53T, A30P, E46K, H50Q or G51D) (Kruger et al. 1998; Polymeropoulos et al. 1997; 
Zarranz et al. 2004; Appel-Cresswell et al. 2013; Lesage et al. 2013) and 
duplications/triplications in SNCA (Singleton et al. 2003; Chartier-Harlin et al. 2004; Ross et 
al. 2008) in familial PD. Polymorphisms in the SNCA promoter confers increased risk of 
idiopathic PD (Pals et al. 2004), polymorphisms in SNCA have been linked with PD risk 
(Kay et al. 2008; Ritz et al. 2012) and drugs that decrease α-syn transcription are associated 
with a reduced risk of PD (Mittal et al. 2017). In summary, there is compelling evidence that 
α-syn has a central role in synucleinopathies. 
α-Syn exists in a dynamic equilibrium between a soluble and membrane-bound state 
and the interaction with lipid surfaces is believed to mediate its cellular functions (Burre 
2015). In the cytosol, α-syn is an intrinsically unstructured monomer with a natively unfolded 
state (Weinreb et al. 1996; Kim 1997; Fauvet et al. 2012a; Burre et al. 2013) . α-Syn was 
later reported to exist as a metastable tetramer (Bartels et al. 2011; Wang et al. 2011), though 
other studies reported contrary evidence (Fauvet et al. 2012b; Burre et al. 2013; Binolfi et al. 
2012; Smaldone et al. 2015) and the formation of multimers is now thought to result from α-
syn interacting with lipid membranes (Burre et al. 2014) (Fig. 1). 
 
α-Syn aggregation 
The aggregation of α-syn from a disordered monomer to highly organized fibrils is 
strongly implicated in the pathogenesis of synucleinopathies. In vitro studies suggest that 
aggregation of α-syn is a nucleation-dependent process characterized by an initial lag phase, 
followed by a growth phase known as “elongation” (El-Agnaf et al. 1998; Wood et al. 1999; 
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Cremades et al. 2012). During the lag phase, there is an accumulation of oligomers (soluble 
species without fibrillar conformation) which, over time, develop into fibrils (El-Agnaf et al. 
2003b; Paleologou et al. 2005; El-Agnaf et al. 2006; Paleologou et al. 2009; Tokuda et al. 
2010). There is converging evidence to indicate that intermediate oligomers or protofibrils 
are particularly cytotoxic (El-Agnaf et al. 2003a; Winner et al. 2011; Helwig et al. 2016), and 
that late stage Lewy bodies, composed primarily of α-syn fibrils, may be less toxic (Bengoa-
Vergniory et al. 2017; Caughey & Lansbury 2003). Such a proposition is consistent with 
neuropathological studies reporting widespread Lewy body pathology without clinically 
significant motor or cognitive symptoms (Frigerio et al. 2011; Parkkinen et al. 2005) and the 
lack of relationship between severity of Lewy body deposition and important clinical 
variables such as disease duration or severity (Colosimo et al. 2003; Parkkinen et al. 2008). 
 Despite the evidence that oligomeric α-syn is particularly neurotoxic, in vitro studies 
have also reported that pre-formed α-syn fibrils can also seed aggregation of monomeric α-
syn and are cytotoxic to cultured neurons (Luk et al, 2012; Pieri et al, 2012; Prusiner et al, 
2015; Peelaerts et al, 2015). It may be the case that oligomers exert their toxicity by further 
developing into fibrillar forms, or that there are a diversity of α-syn aggregates of differing 
cytotoxicity. Therefore, it remains unclear as to which strain of α-syn is most toxic, with the 
lack of characterization of distinct strains of α-syn impeding efforts to address this question. 
Nevertheless, post-mortem studies have reported that the abundence of Lewy bodies 
composed of tightly aggregated α-syn fibrils are predictive of important clinical variables 
such as disease duration or severity (Colosimo et al., 2003; Parkkinen et al.,2008). Whilst 
there is compelling evidence for a central role for α-syn in synucleinopathies, Lewy bodies 
may not be directly responsible for eliciting clinical features but may rather be a useful 
neuropathological marker of a process that produces cytotoxic aggregates (Ansorge et al. 
1997; Milber et al. 2012).    
The growing realization that Lewy body severity relates poorly to important clinical and 
pathological variables has stimulated interest in the search for α-syn proteoforms that may be 
more relevant to the disease process, with considerable interest focused on oligomeric forms 
that precede the formation of fibrils. Oligomeric α-syn has been observed in degenerating 
neurons of PD patients, tying it more directly to neuronal degeneration than Lewy bodies 
(Sharon et al. 2003; Tofaris et al. 2003). A direct link between α-syn oligomer exposure and 
cell death has been demonstrated with in vitro studies reporting a direct relationship with cell 
death (Chen et al. 2007; Danzer et al. 2007; Nasstrom et al. 2011). Studies in model 
organisms have also demonstrated that oligomeric α-syn is capable of inducing cell death, 
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with dopaminergic neurons especially vulnerable (Karpinar et al. 2009; Winner et al. 2011; 
Outeiro et al. 2008; Dimant et al. 2013). The exact mechanism of α-syn oligomer-induced 
neurotoxicity is not clear; however, disruption of the following cellular effects have been 
proposed: 1) disruption of the mitochondrial morphology (Poehler et al. 2014; Chinta et al. 
2010; Luth et al. 2014; Lindstrom et al. 2017); 2) increased endoplasmic reticulum stress 
(Colla et al. 2012b; Colla et al. 2012a; Castillo-Carranza et al. 2012); 3) inhibition of the 
ubiquitin-proteasome system (Lindersson et al. 2004; Emmanouilidou et al. 2010); 4) 
acceleration of membrane damage (Caughey & Lansbury 2003; Danzer et al. 2007); and 5) 
synaptic dysfunction (Choi et al. 2013; Schulz-Schaeffer 2010). The putative view that 
oligomers both precede the formation of, and are more cytotoxic than, Lewy bodies raises the 
question of why Lewy bodies are  abundant in end-stage post-mortem brain tissue as 
oligomers would likely induce cell death prior to Lewy body formation. However, along with 
on-pathway prefibrillar oligomers, which eventually lead to mature fibrils, off-pathway stable 
oligomers might contribute to sustained toxicity (Lee et al. 2018). Furthermore, it is possible 
that Lewy body-bearing neurons are cells that have survived the initial oligomer-mediated 
cellular insult, and that they therefore should be viewed as markers of resilient neurons.   
 
α-Synuclein as a target for diagnosis  
 
 Current diagnoses of synucleinopathies are based upon the constellation of clinical 
features, often coupled with supportive neuroimaging. However, symptoms in PD are only 
apparent when approximately 50-70% of nigral neurons are lost, implying that substantial 
neurodegeneration occurs before the disease is clinically detectable (Ross & Pickart 2004; 
Dauer & Przedborski 2003). DLB and MSA are thought to be substantially under-diagnosed 
(Kane et al. 2018; Joutsa et al. 2014), suggesting that current diagnostic methods are not 
sensitive enough to identify these disorders. Therefore, the development of biomarkers that 
can enable rapid and early differential diagnosis is a healthcare priority.  
 Among biochemical biomarkers, α-syn has been extensively studied as a candidate 
biomarker for PD in biological fluids especially in serum, plasma and cerebrospinal fluid 
(CSF) (Aasly et al., 2014; Gorostidi et al., 2012; Kasai et al., 2014; Simonsen et al., 2016; 
Landeck et al., 2016; Majbour et al., 2017; Mollenhauer et al., 2017). Some studies have 
reported decreased levels of total α-syn (t-α-syn) in CSF from patients with PD compared to 
control (Tokuda et al. 2006; Mollenhauer et al. 2008; Hong et al. 2010; Parnetti et al. 2011; 
Mollenhauer et al. 2011). However, measuring levels of t-α-syn alone does not distinguish 
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patients with PD from other synucleinopathies and there is a considerable overlap between 
patient and control groups (Mollenhauer et al. 2011). Soluble α-syn oligomers are elevated in 
brain homogenates from PD and DLB compared to control and, therefore, detection of α-syn 
oligomers in CSF and/or blood has been proposed as a potential biomarker (Paleologou et al. 
2009; Sharon et al. 2003; Tokuda et al. 2010; El-Agnaf et al. 2006). Furthermore, the 
sensitivity and specificity of oligomeric α-syn is increased when it is calculated relative to t-
α-syn (Tokuda et al. 2010; Parnetti et al. 2014; Hansson et al. 2014; Aasly et al. 2014; 
Majbour et al. 2016a; Majbour et al. 2016b). More recently, α-syn phosphorylated at S129 
(p-S129-α-syn) has been proposed as a potential biomarker for PD and related disorders 
(Wang et al. 2012; Majbour et al. 2016b; Karampetsou et al., 2017). P-S129-α-syn is 
increased in PD CSF and, as with oligomeric α-syn, calculating the ratio of both α-syn 
oligomers/ t-α-syn as well as the ratio of p-S129-α-syn/t-α-syn increased the discriminating 
power between PD and healthy controls (Majbour et al. 2016b). Taken together, these studies 
indicate that identification and quantification of distinct α-syn proteoforms may have greater 
discriminative power than t-α-syn in identifying disease cases. However, the increased 
sensitivity conferred by evaluating such proteoforms relative to t-α-syn may suggest that 
synucleinopathies are characterized by dyshomeostasis of distinct α-syn proteoforms, rather 
than simple elevations in one particular sub-type.   
 
Importance of antibodies in research/ diagnosis/ treatment  
 
Antibodies (also known as immunoglobulins) are large Y-shaped proteins that are 
found in the blood or other body fluids of vertebrates. Antibodies are the key element of the 
adaptive immune system and recognize a unique part of foreign targets called antigens. 
Antibodies have several classes, of which immunoglobulin G (IgG) is most commonly used 
in biological studies. IgG antibodies are made and secreted by B cells and have the ability to 
recognize specific antigens. The IgG is made up of two subunits including two heavy chains 
and two light chains, assembled in a symmetrical structure. Each IgG has two identical 
antigen recognition domains, a Fab region and a constant stem region (Fc) that is common 
among the various classes of antibodies and is not involved in antigen recognition. 
Antibodies can be divided into monoclonal antibodies, that bind a single epitope, and 
polyclonal antibodies that recognize multiple epitopes on the same antigen.   
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Antibodies are commonly used to localize a specific antigen in tissue 
(immunohistochemistry), to quantitate the antigen by radioimmuoassay (RIA) or an enzyme-
linked immunosorbent assay (ELISA), as affinity reagents in protein purification, to detect an 
antigen in tissue samples (western blotting), to concentrate an antigen (immunoprecipitation), 
and to neutralize an antigen. Due to the high binding specificity with the target antigen, and 
the ability to quantitate the amount of antigen within a sample using antibody-based assays, 
antibodies are widely used for diagnostics, fundamental studies probing disease mechanisms 
and, increasingly, therapeutics.  
 
α-Syn specific antibodies: invaluable tools for synucleinopathy research 
Several antibodies against α-syn have been developed (listed in Table 1) since it was 
first detected as the major component of LBs and Papp-Lantos bodies/GCIs (Spillantini et al. 
1997; Spillantini et al. 1998b). α-Syn along with β-syn was identified in cytosolic extracts of 
the human brain using immunoblots with antibodies against phosphorylated tau proteins 
(Jakes et al. 1994).  Subsequently, antibodies generated against purified Lewy bodies (Baba 
et al. 1998), the NAC region (amino acids 65-90), the N-terminal region and C-terminal 
region strongly label Lewy bodies (Culvenor et al. 1999; Dickson et al. 1999). However, 
antibodies raised against native α-syn likely label all or most α-syn within the brain, 
including the endogenous protein found in non-diseased brain, and may thus lack disease-
specificity. The typically poor relationship between α-syn immunoreactivity, as identified 
using pan-α-syn antibodies, and important clinical variables such as phenotypic severity may 
be due to the fact that these antibodies can not distinguish changes in α-syn proteoform 
homeostasis, particularly proteoforms (oligomers/protofibrils) of putative disease importance.    
 
In order to discriminate α-syn conformational forms, attempts were also made to 
generate single chain antibodies (scFvs) using the human phage antibody library (Maguire-
Zeiss et al. 2006; Emadi et al. 2007; Nannenga et al. 2008). The localization of α-syn in 
neuronal nuclei in the brain was identified using antibodies raised against the full-length α-
syn with an epitope mapped at the C-terminal region (amino acids 115-121) (Yu et al. 2007). 
The modified form of α-syn, including in vitro oxidized/nitrated forms, were also used to 
generate antibodies, showing extensive underappreciated α-syn pathology in the brains of 
diseased patients (Duda et al. 2002; Waxman et al. 2008). Aggregated α-syn, formed by 
treatment with either high salt or acid conditions, generated antibodies with high reactivity to 
disease associated α-syn (Mougenot et al. 2010; Kovacs et al. 2012). Owing to the role of α-
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syn oligomers in the pathogenesis of synucleinopathies, modified oligomeric forms of α-syn 
induced by 4-hydroxy-2-noneal, have also been employed for generating antibodies 
(Fagerqvist et al. 2013). More recently, approaches have been developed either to generate 
either conformation-specific antibodies (Brannstrom et al. 2014; Covell et al. 2017) or 
antibodies targeting specific epitope within aggregated proteins using complementary peptide 
designs and grafting procedures (Sormanni et al. 2015).  
Recently we have developed conformation-specific monoclonal antibodies that 
specifically recognize α-syn oligomers/protofibrils or fibrils with high affinity, without cross-
reacting with monomers (Vaikath et al. 2015). The ability of these antibodies to specifically 
recognize aggregates of α-syn and not monomers or fibrils generated from other 
amyloidogenic proteins, makes them unique since most antibodies with conformational 
epitopes will cross-react with other proteins with similar conformations (Vaikath et al. 2015). 
Cross reactivity with proteins of similar conformations is a major problem in 
neurodegenerative disease research as the aged brain is characterized by many protein 
aggregates, many of which adopt similar conformations in pathological conditions (Attems & 
Jellinger 2013). These conformation-specific antibodies were able to label distinct burdens of 
Lewy pathology (Fig. 2). Furthermore, the conformational specificity of these antibodies 
have been utilized to detect α-syn aggregates in biochemical studies (Leung et al. 2015), in 
neurons of C. elegans (Kim et al. 2016) and rats (Duffy et al. 2018), guinea-pig ileum 
(Sharrad et al. 2017) human skin biopsy of patients with idiopathic PD (Donadio et al. 2018) 
and in human post mortem brain tissues from PD, DLB, AD and control cases (Vaikath et al. 
2018)  
 
Engineering Antibody fragments 
 Although antibodies are considered the “gold standard” in biomedical research and 
biofluid-based diagnostic assays, their therapeutic potential is undermined by their high 
molecular weight. This is a particular problem for neurological disorders as entrance of 
antibodies into the brain is inhibited by the blood-brain-barrier (BBB). Therefore, researchers 
have exploited the modular nature of antibodies to engineer customized antibody fragments 
without hindering their affinity or specificity. Recombinant antibody fragments including 
monovalent antibody fragments (Fab and scFv) and engineered variants, including diabodies, 
triabodies, minibodies and single-domain antibodies, are now emerging as replacements for 
full-length antibodies. In therapeutics, these fragments have higher penetrability in the 
tissues, including the brain, and faster clearance. They can be used to build multi-specific 
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antibody formats with high avidities. Moreover, their production in large quantities uses 
bacterial or yeast systems, and thus high quantities can be made in a more efficient and 
economic manner. The best-known form is scFv whose VH and VL domains are linked by a 
flexible polypeptide preventing their dissociation (Bird et al. 1988).  
 Another option is represented by the use of bifunctional antibodies. Recently, it has 
been demonstrated that amyloid-β:transferrin receptor antibodies have a high BBB 
penetrance and can be applied for efficient PET imaging and immunotherapy on an 
Alzheimer’s disease mouse model (Sehlin et al. 2016; Syvanen et al. 2018). A similar 
strategy could possibly be applied towards α-syn for improved diagnostic and therapeutic 
strategies in synucleinopathies. 
 
Antibody fragments targeting -syn 
 In recent years, various antibody fragments have been generated to target -syn. Zhou 
et al developed scFv fragments that bind and stabilize monomeric -syn and thus prevent the 
formation of intracellular high molecular weight species (Zhou et al. 2004). scFv were also 
utilized to develop sensitive phage based capture ELISA to detect the protein from clinical 
samples with femtomolar range  (Williams et al. 2015). Barkhordarain et al. (2006) combined 
the capabilities of phage display antibody technology and atomic force microscopy to isolate 
scFv antibody fragments that bind to a specific morphology of -syn from synthetic libraries 
(Barkhordarian et al. 2006). Furthermore, scFvs have been isolated from a naïve human scFv 
library that was found to inhibit the aggregation of various amyloid proteins, and attenuate 
amyloid oligomer-induced cytotoxicity in vitro (Wang et al. 2009). These scFv recognized 
amyloid oligomers in all types of plaques, Lewy bodies, and amylin deposits in the brain 
tissues of AD and PD patients and in the pancreas of type 2 diabetes patients (Wang et al. 
2009).  Other scFv antibodies, including 10H and D5, were found to recognize 
morphologically distinct α-syn oligomers and selectively bind to aggregates in post-mortem 
human PD brain tissues and inhibit toxicity in a cell model (Emadi et al. 2007; Emadi et al. 
2009) Recently, scFv W20 that recognizes various oligomers targeting the common epitopes 
of amyloid oligomers was found to reduce α-syn and mutant huntingtin protein aggregate 
load in mouse models, leading to reduced synaptic degeneration, neuroinflammation and 
oxidative stress, concomitant with amelioration of cognitive and motor deficits (Zha et al. 
2016). Spencer et al. (2014) fused the scFv fragment, targeting oligomeric -syn, to low 
density lipoprotein receptor-binding domain from apolipoprotein B, improving its therapeutic 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
potential by increasing accumulation of scFv in the brain and directing scFv/α-syn complexes 
for degradation through the endosomal sorting pathway (Spencer et al. 2014). They 
demonstrated that scFv directed against oligomeric α-syn (clone CD5-D5) expressed 
peripherally with lentiviral vectors (LV-CD5-D5-apoB) penetrates into the CNS and reduces 
the accumulation of wild-type α-syn, but not mutated α-syn associated with familial PD, in 
vivo (Spencer et al. 2014). Although nanobodies were found to be effective, their intracellular 
solubility can be low, Joshi et al (2012) demonstrated that fusing scFv intrabody with the 
proteasome-targeting PEST motif increased solubility whilst apparently also improving the 
functionality of the nanobody (Joshi et al. 2012). 
 
Nanobodies targeting -syn 
 A potential alternative to scFV antibodies are single domain antibodies, sometimes 
termed nanobodies, occurring in Camelidae (Hamers-Casterman et al. 1993). Like scFvs, 
nanobodies have high solubility and, with a molecular weight of 15 kDa, are capable of 
traversing the blood-brain-barrier. Nanobodies also bind antigens in the sub-nanomolar range 
and can be efficiently cloned in bacteria or yeast at relatively low cost. Among the first 
nanobodies generated against -syn was NbSyn2 (Vuchelen et al. 2009) recognizing the C-
terminus of human α-syn. Using a range of biophysical techniques, the epitopes of NbSyn2 
and another nanobody, NbSyn87, were demonstrated to still be accessible when α-syn 
converts into its fibrillar structure, meaning they can label α-syn fibrils at different maturation 
stages (Guilliams et al. 2013). From a therapeutic perspective, NbSyn2 and NbSyn87 reduce 
oligomer-induced cellular toxicity in vitro, with important implications for future therapeutics 
(Iljina et al. 2017).  
 
Therapeutic strategies in synucleinopathies 
In addition to the continued use of antibodies for research and diagnosis, they are also 
currently being evaluated as potential therapeutic agents due to their high specificity, high 
binding affinity, long half lives and low toxicity. There is no disease-modifying therapy for 
any synucleinopathy but previous approaches have focused on reducing α-syn expression 
using antisense oligonucleotides (Murphy et al. 2000), miRNA (Junn et al. 2009) or siRNA 
(Spencer et al., 2019), decreasing α-syn aggregation with small molecules (Ardah et al., 
2014; Ardah et al., 2015; Paleologou et al., 2005; Wrasidlo et al. 2016), increasing the 
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clearance of α-syn via autophagy (Sarkar et al. 2016) and preventing the seeding and prion 
like spreading of α-syn (Valera et al. 2016). 
Currently, immunotherapeutic approaches are being explored as a potential disease-
modifying treatment for synucleinopathies. Both active and passive immunotherapeutic 
approaches are being tested as a treatment strategy for various synucleinopathies. Recently, 
active immunotherapy, using PD01 (AFFiRiS AG), is reported to be under Phase 1 clinical 
trials (Valera & Masliah 2013). PD01 is a peptide-based vaccine that was found to reduce 
cerebral α-syn levels and ameliorate neuropathological alterations in mouse models of 
synucleinopathies (Schneeberger et al. 2012; Valera & Masliah 2013). Passive 
immunotherapy using antibodies against α-syn has been shown also to protect against 
neurodegeneration and reduce α-syn accumulation by triggering clearance via autophagy 
(Mandler et al. 2014; Masliah et al. 2011; Masliah et al. 2005). Likewise, monoclonal 
antibodies targeting NAC and C-terminal of α-syn ameliorated behavioral deficits, reduced 
nuerodegeneration and α-syn accumulation in neurons (Masliah et al. 2011) and glial cells 
(Bae et al. 2012).  Immunotherapeutic approaches targeting the amyloid-β peptide have 
been the subject of several recent high-profile failures in phase III clinical trials in AD, 
prompting the suggestion that the wrong species of amyloid-β was engaged (Panza et al, 
2019). In LB disease research, there are a paucity of studies fully characterizing the diversity 
and complexity of α-syn aggregates in the diseased brain with the aim of understanding those 
of greatest pathogenic relevance. As a previous study reported that antibodies generated 
against synthetic forms of α-syn characterized by high molecular weight species have little 
predictive and, presumably, therapeutic value (Woerman et al, 2018), future approaches may 
better approach this question by focusing on lower molecular weight species or isolated 
species from post-mortem brain tissue. Most previous studies have employed antibodies 
targeting monomeric or fibrillar α-syn. The detection of α-syn oligomers in the extracellular 
space (El-Agnaf et al. 2006; Tokuda et al. 2010; Lee et al. 2006) and its cell-to-cell 
propagation (Volpicelli-Daley et al. 2014; Danzer et al. 2012; Danzer et al. 2011; Luk et al. 
2012; Helwig et al., 2016) makes it an ideal candidate target for immunotherapy. In a 
previous study, it was demonstrated that antibodies with strong selectivity towards α-syn 
oligomers/protofibrils could decrease α-syn pathology both in a cell model for α-syn 
aggregation and in the CNS of transgenic mice expressing the A30P variant of human α-syn 
(Nasstrom et al. 2011; Lindstrom et al. 2014). Furthermore, we have demonstrated that 
immunization with conformation-specific monoclonal antibodies reduces α-syn accumulation 
and related deficits in wild type α-syn transgenic (line 61) mice (El-Agnaf et al. 2017). 
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Moreover, the antibodies were most effective at reducing accumulation of α-syn oligomers in 
multiple brain regions and at preventing neurodegeneration (El-Agnaf et al. 2017). Therefore, 
immunotherapeutic targeting of α-syn oligomers holds considerable promise in the continued 
search for disease-modifying therapies for α-synucleinopathies. 
There remains a legitimate question as to the timing of immunotherapeutic strategies 
in neurodegenerative proteopathies, with the criticism of such approaches being employed 
too late in the natural history of disease frequently used as post-hoc explanations of failure. It 
seems likely that immunotherapeutics will be most efficacious if applied early in the disease 
course, thus further underscoring the necessity of developing effective biomarkers to support 
early accurate diagnosis. 
 
Conclusion 
Relatively little is currently understood about how the protein α-syn contributes to the 
clinical and pathological features that characterize synucleinopathies. Many studies have 
evaluated α-syn using pan-α-syn antibodies that do not distinguish between proteoforms of 
likely differing clinical relevance, which may account for inconsistent findings tying α-syn 
expression with important clinical and pathological variables. It is evident that the knowledge 
base on the diversity of α-syn proteoforms and their clinical and pathological relevance is 
incomplete, and thus further studies are warranted to identify novel α-syn proteforms that 
may be potentially useful diagnostic and therapeutic targets. It is also likely that different 
strains of α-syn have different seeding capacities and thus the relative abundance of distinct 
species may be predictive of the rate of pathological propagation and, therefore, speed of 
functional decline. We suggest that there is a pressing need for further characterization of the 
diversity and clinico-pathological relevance of distinct strains of α-syn in LB disease. 
Antibody-based approaches across the translational spectrum, from discovery science to 
therapeutic targeting, are an excellent platform to accelerate discovery in this area.  
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Figure Legends 
 
Figure. 1 
α-Syn under physiological and pathological conditions.  
Under physiological conditions, α-syn is an unstructured soluble monomer bound to 
membranes with two α-helices. Under pathological conditions, α-syn dimerizes and 
subsequently aggregates into oligomers/protofibrils, which ultimately form into mature 
fibrils. 
 
Figure. 2 
Conformation-specific antibodies label distinct burdens of Lewy pathology. Staining of the 
cingulate gyrus, a region prone to Lewy body deposition, in serial sections from a DLB case 
reveals distinct patterns of immunoreactivity. Antibodies against oligomeric α-syn (Syn-O1 
and Syn-O2) label numerous fine neuritic structures in addition to larger Lewy bodies, whilst 
antibodies against fibrillar species (Syn-F1 and Syn-F2) label fine dots and Lewy bodies. 
Scale bars = 50 μm.  
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Table1. List of α-syn antibodies  
 
Sl No Antibody Clonality Host Form Antigen Specificity Tested application Ref 
1 LB509 mAb Mouse 
Culture 
supernatan
t 
LB purified from 
DLB cortices 
Generic 
IHC, Western blot 
Baba et al., 
1998 
2 Syn202 
mAb Mouse Purified 
Recombinant full 
length α-syn  
Generic 
Giasson et al., 
2000 
3 Syn204 
4 Syn205 
5 Syn208 
6 Syn211 
7 Syn214 
8 SNL-1 pAb Rabbit Purified 
Recombinant full 
length α-syn  
Generic  IHC, Western blot 
9 SNL-4 pAb Rabbit Purified 
Recombinant full 
length α-syn  
Generic  IHC, Western blot 
10 PER1 pAb  Rabit Antiserum amino acid 11-34   
Immunoelectron 
microscopy 
Crowther et 
al., 2000 
11 PER4 pAb  Rabit Antiserum 
Recombinant full 
length α-syn  
Generic  
12 H3C mAb  Mouse Purified 
129-143 of Zebra 
Finch 
  
13 nSyn8 
mAb Mouse Purified nitrated α-syn  
  
Generic  
  
ELISA, IHC, Western 
blot 
Giasson et al 
b., 2000 
14 nSyn14 
15 nSyn24 
16 Anti-3NT pAb Rabbit Purified  nitrated α-syn   Generic     
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17 Syn 303 mAb Mouse  Purified  
Oxidized α-syn  
 Generic 
  
  
IHC, Western blot 
Duda et al., 
2002; 
Waxman et al 
., 2008 
18 Syn 505 mAb Mouse  Purified  
19 Syn 514 mAb Mouse  Purified  
20 Syn1 mAb Mouse Purified rat α-syn   Generic Western blot 
Perrin et al., 
2003 
21 FILA-1 pAb Rabbit Purified 
Sucrose density 
gradient-purified α-
syn  filaments  
Generic  
Dot blot, Solid phase 
binding assay 
Lindersson et 
al., 2004 
22 15 G7 mAb  Mouse Purified  Synthetic peptide  Generic  
IHC 
Croisser et al., 
2006 
23 42 mAb  Mouse   Purified 
Rat synuclein amino-
acid 15-123  
 Generic 
24 7B 2, 12 mAb Mouse   Purified 
Recombinant full 
length α-syn  
 Generic 
25 KM51  mAb Mouse   Purified 
Recombinant full 
length α-syn  
 Generic 
26 NAC1 
scFv 
Yeast 
display 
library 
 Purified 
non-immune human 
scFv library  
Generic  Western Blot 
Lynch et al., 
2008 
27 NAC3 
28 NAC6 
29 NAC14 
30 NAC24 
31 NAC32 
32  Panel of anibodies  pAb Rabbit   Purified 
α-syn peptide 
corresponding to 
different regions 
 Generic  ELISA, Dot blot 
Masuda et al., 
2009 
33 NbSyn2 Nanobody NA  Purified 
Recombinant full 
length α-syn  
Generic    
Vuchelen et 
al., 2009; De 
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Genst et al., 
2010 
34 AS11 mAb Mouse  Purified Modified α-syn   Generic 
Western blot, IHC, 
immunofluorescence 
Mougenot et 
al., 2010 
35 2 E 3 
mAbs Mouse  ND 
α-syn recombinant 
protein  
 Generic IHC 
Vivacqua et 
al., 2011 36 2 D 5 
37 9 E 4  mAb Mouse  ND 
α-syn recombinant 
protein  
    
Masliah et al., 
2011 
38 mAb49/G mAb Mouse Purified  
HNE-induced α-syn 
oligomers 
Conformation-
specific  
ELISA, 
Immunocytochemistry 
Nasstrom et 
al., 2011 
39 5G4 mAb Mouse Purified  
α-syn peptide 
corresponding to 
amino acids 44-57  
Generic  
ELISA, 
Immunocytochemistry 
Kovacs et al., 
2012 
40 mAb38F 
mAbs Mouse Purified  
HNE-induced α-syn 
oligomers 
Conformation-
specific  
ELISA, 
Immunocytochemistry 
Fagerqvist et 
al., 2013 41 mAb38E2 
42 Syn-F1 
mAbs Mouse Purified 
Recombinant full 
length α-syn  
 Conformation-
specific 
Dot blot, ELISA, IHC 
Vaikath et al., 
2015 
43 Syn-F2 
44 Syn-O1 
45 Syn-O2 
46 Syn-O3 
47 Syn-O4 
48 11D12 mAb Mouse Purified 
Recombinant full 
length α-syn  
Generic Dot Blot, Western blot 
Majbour et al., 
2016b 
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49 PS129 mAb Mouse Purified 
α-syn peptide 
corresponding to 
amino acids 125-123 
phosphorylated at 
S129 
Phospho-speicfic Dot Blot, Western blot 
50 Syn-140 pAb Sheep Purified 
Recombinant full 
length α-syn  
Generic  Western blot 
51 A1-A6  mAbs Mouse   Purified  
Recombinant full 
length α-syn 
monomer-aggregate 
mixture  
Generic  Dot blot 
Sahin et al., 
2017 
52 Syn7015 
mAbs Mouse  ND 
sonicated, cross-
linked α-syn stain A 
PFFs  
Conformation-
specific 
IHC 
Covell et al., 
2017 
53 Syn9029 
54 
A panel of 
antibodies 
mAbs Mouse  ND  
α-syn peptide 
corresponding to N 
and C-terminal  
Generic  Western blot, IHC 
Dhillon et al., 
2017 
 
*ND: mAb: monoclonal antiobdy; pAb: Polyclonal antibody; ND: Not defined; WB: Western blot; IHC: Immununohistochemistry;  
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